Clinical trial

Firmagon (Degarelix) Intermittent Therapy

NCT01512472

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE4

Study timeline

Study start (unknown)2012-01-01Date precision: month

Registry last updated2019-09-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancer Recurrentunresolved

Interventions

degarelixDRUG · verified · RxNorm: degarelix

Sponsors & collaborators

Canadian Urology Research Consortiumlead sponsor

Ferring Pharmaceuticalscollaborator

Mapped research locations

TorontoOntario, Canada2 MontrealQuebec, Canada2 VancouverBritish Columbia, Canada1 OttawaOntario, Canada1 LondonOntario, Canada1 HamiltonOntario, Canada1 QuébecQuebec, Canada1 WinnipegManitoba, Canada1 HalifaxNova Scotia, Canada1 KingstonOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01512472 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.